Loading...
Loading...
Browse all stories on DeepNewz
VisitNew Alzheimer's Treatment with DDL-920 Flips Memory Back On
Aug 9, 2024, 06:28 PM
Researchers at Sungkyunkwan University in South Korea have developed a novel approach to improve Alzheimer's treatment using light-activated exosome protein delivery. Additionally, a new molecular compound named DDL-920 has been created to enhance memory function in Alzheimer's patients. This compound works by inhibiting the action of GABA, a chemical messenger that dampens gamma oscillations in fast-firing structures known as parvalbumin neurons. This approach shifts focus from combating plaques linked to Alzheimer's to boosting electrical oscillations in the brain, showing promise in reversing Alzheimer's symptoms. The new compound effectively flips memory back on in Alzheimer's cases.
View original story
Markets
Yes • 50%
No • 50%
Major medical journals such as The Lancet, JAMA, or NEJM
No • 50%
Yes • 50%
Press releases from Sungkyunkwan University and South Korean pharmaceutical companies
No • 50%
Yes • 50%
FDA official announcements and press releases
United States • 25%
Other • 25%
South Korea • 25%
European Union • 25%
Regulatory agency announcements from respective regions
Roche • 25%
Other • 25%
Pfizer • 25%
Novartis • 25%
Press releases from pharmaceutical companies and Sungkyunkwan University
Other • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Market analysis reports from firms like Gartner, McKinsey, or Bloomberg